Reynold Lemkins Backs Visen Pharmaceuticals IPO, Strengthening Cross-Border Investment in AI-Driven Healthcare
Official Announcement of Investment Participation
Reynold Lemkins Group is pleased to announce its investment in Visen Pharmaceuticals’ IPO on the Hong Kong Stock Exchange, reaffirming our commitment to advancing medical innovation and cross-border healthcare investments.
As a late-stage biotech firm, Visen Pharmaceuticals is on the cusp of commercialization, focused on developing next-generation treatments for endocrine disorders. The company’s lead product — Lonapegsomatropin, a long-acting growth hormone therapy — has already received FDA approval in the U.S. and represents a major step forward in personalized pediatric care.
Due to overwhelming institutional demand, Visen Pharmaceuticals successfully raised USD $100 million, exercising its over-allotment option to expand the offering. This makes it the largest biotech IPO since the second half of 2023, marking a significant milestone for the sector and reinforcing strong investor confidence in Visen’s commercialization strategy and global market potential.
Co-Investing Alongside Top-Tier U.S. & Global Investors
The IPO attracted a remarkable slate of institutional investors from both the U.S. and China, reinforcing strong market confidence in Visen Pharmaceuticals’ pipeline and strategic direction. Key co-investors include:
• Ascendis Pharma (NASDAQ: ASND) — The U.S. biotech company that originally developed Lonapegsomatropin
• Sequoia China, Sofinnova, Vivo Capital, and OrbiMed — Renowned global investors focused on healthcare innovation
• WuXi Biologics (HKEX: 2269) — A leading biologics manufacturer with global scale and capabilities
Reynold Lemkins’ participation alongside these world-class investors reflects our conviction in the company’s future trajectory and aligns with our broader strategy of supporting impactful biotech companies at critical inflection points.
“Visen Pharmaceuticals represents the type of global innovation Reynold Lemkins is proud to support — one that combines scientific rigor, proven regulatory success, and a scalable vision for impact across borders. As we continue to invest at the intersection of healthcare and deep technology, this IPO underscores our belief that Asia will play a pivotal role in shaping the future of global biotech.”
— Kris Haoran Liu, President and Chief Investment Officer, Reynold Lemkins Group
Commitment to Healthcare Innovation & Bridging Technologies to Asia
At Reynold Lemkins, we believe AI and data-driven therapeutics will define the next era of healthcare. Our investment in Visen Pharmaceuticals is a direct extension of that thesis.
The company represents a rare convergence of FDA-approved science, Asia market entry, and scalable infrastructure — with IPO proceeds dedicated to expanding the availability of Lonapegsomatropin in China and the broader Asia-Pacific region.
As a cross-border investment platform, Reynold Lemkins is proud to act as a strategic bridge — supporting global healthtech companies as they expand into Asia through capital, partnerships, and market intelligence.
Focus on Capital Markets & Secondary Market Strategy
While Visen Pharmaceuticals is nearing commercialization, its post-IPO journey will require thoughtful navigation of capital markets, institutional engagement, and secondary market strategy. Reynold Lemkins brings extensive expertise in managing IPO after-market performance, fostering investor confidence, and unlocking long-term value.
We also recognize the growing importance of the Hong Kong Stock Exchange (HKEX) as a hub for biotech listings — bridging the East-West capital markets ecosystem and positioning Hong Kong as a gateway for healthcare innovation.
Our investment in Visen Pharmaceuticals is part of a broader strategy to identify and scale late-stage biotech and AI-powered medical ventures in public markets.
Looking Ahead: Our Ongoing Commitment to Medical Innovation
Reynold Lemkins’ participation in Visen Pharmaceuticals’ IPO reaffirms our belief in the transformative power of biotech innovation, especially when paired with smart commercialization strategies and global capital partnerships.
We will continue to seek out exceptional founders, pioneering technologies, and strategic partnerships that redefine patient care across borders.
To health, to innovation, and to the future — this is just the beginning.
